





Metadichol and Corona Virus



syndrome), another coronavirus, researchers discovered that one of the ways the disease attaches itself is through an enzyme known as ACE2, a functional receptor' produced in several organs (oral and nasal mucosa, nasopharynx, lung, stomach, small intestine, colon, skin, lymph nodes, thymus, bone marrow, spleen, liver, kidney, and brain). ACE2 is also "abundantly present in humans in the epithelia of the lung and small intestine, which might provide possible routes of entry for the SARS CoV," while it was also observed "in arterial and venous endothelial cells and arterial smooth muscle cells" – which would include the heart. Evidence of both sudden collapses and neurological damage from footage pouring out of Wuhan, China







VDR controls expression of FURIN

Data Sources

Molecular Signatures Database


VDR controls state change of SRC

VDR interacts with SRC

The virus uses the outreaching spike protein to hook on to the host cell, but normally this protein is inactive. The cleavage site structure's job is to trick the human furin protein, so it will cut and activate the spike protein. The activation causes a "direct fusion" of the viral and cellular membranes. Compared to the Sars virus's way of entry, this binding method is "100 to 1,000 times" as efficient, according d by Professor Li Hua from Huazhong University of Science and Technology in Wuhan, Hubei province, . Drugs targeting the furin enzyme, including HIV medicines, could have the potential to hinder the virus's replication in the human body,


The attachment protein "spike" of the new coronavirus SARS-CoV-2 uses the same cellular attachment factor (ACE2) as SARS-CoV and uses the cellular protease TMPRSS2 for its activation. Existing, clinically approved drugs directed against TMPRSS2 inhibit SARS-CoV-2 infection of lung cells. A cellular protein called TMPRSS2, is crucial for the entry of the novel coronavirus into lung cells. The

results of the study show that the virus needs the protease, which is present in the body, to enter the cells, providing a new target for therapeutics.



Hoffmann, M et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically-proven protease inhibitor. Cell, https://marlinprod.literatumonline.com/pb-

assets/journals/research/cell/CELL_S0092-8674%2820%2930229-4.pdf



Metadichol® can regulate ACE 2 through its expression of IRS1. In Addition VDR binding to SRC leads to regualtion of FURIN And Finally VDR controls expression of PPARG which controll AR another Nuclear receptor that leads to TMPRSS2 and thus all elements needed are presnt to onhibit the Corona Virus by Metadichol which may trun out to be a safe novel agent to control the Corona virus.